Otto Metzger, Md

This study tested a new drug called taselisib, which blocks a protein that helps cancer grow, combined with standard HER2-targeted therapies in 68 people with advanced HER2+ breast cancer. The main goal was to find the safest dose for future studies. Researchers also looked at wh…